<DOC>
	<DOCNO>NCT02586415</DOCNO>
	<brief_summary>This study evaluate hypothesis FDA clear thrombectomy device plus medical management lead superior clinical outcome acute ischemic stroke patient 90 day compare medical management alone appropriately select subject Target mismatch profile MCA ( M1 segment ) ICA occlusion randomize endovascular treatment initiate 6-16 hour last see well .</brief_summary>
	<brief_title>Endovascular Therapy Following Imaging Evaluation Ischemic Stroke 3</brief_title>
	<detailed_description>DEFUSE 3 prospective randomize Phase III multicenter control trial patient acute ischemic anterior circulation stroke due large artery occlusion treat 6-16 hour stroke onset endovascular thrombectomy therapy vs. control . The primary endpoint , modify Rankin Score , assess 3 month . The patient ' participation study conclude time ( 3 month stroke onset ) . The study randomize 476 patient 4 year . The purpose DEFUSE 3 ass safety efficacy thrombectomy carefully select patient extended time window . Only device list protocol use . Selection specific device ( device ) determine individual endovascular therapist . Patients meet inclusion criterion undergo either CT Perfusion/CT Angiogram MR DWI/PWI/MRA study prior randomization . Patients evidence ICA MCA M1 occlusion Target Mismatch Profile randomize 1:1 ratio treatment one DEFUSE 3 approve thrombectomy device ( device list protocol approve use DEFUSE 3 ) plus standard medical therapy versus standard medical therapy alone . Patients enrol , randomize , receive standard therapy accord local guideline . Baseline data , information early stroke therapy , capture group patient . Randomization maximum 476 patient plan . A novel adaptive design identify , interim analysis , group best prospect show benefit endovascular treatment , base baseline core lesion volume time since stroke onset . Interim analyse conduct 200 340 patient , time study may stop efficacy/futility , inclusion criterion may adjust case futility .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>Clinical 1 . Signs &amp; symptom consistent w/ diagnosis acute anterior circulation ischemic stroke 2 . Age 1890 year 3 . Baseline NIHSSS ≥ 6 remains ≥6 immediately prior randomization 4 . Endovascular treatment initiate ( femoral puncture ) 6 16 hour stroke onset . Stroke onset defined time patient last know neurologic baseline ( wakeup stroke eligible meet time limit ) . 5. modified Rankin Scale less equal 2 prior qualify stroke ( functionally independent ADLs ) 6 . Patient/Legally Authorized Representative sign Informed Consent form . Clinical 1 . Other serious , advanced , terminal illness ( investigator judgment ) life expectancy le 6 month . 2 . Preexisting medical , neurological psychiatric disease would confound neurological functional evaluation 3 . Pregnant 4 . Unable undergo contrast brain perfusion scan either MRI CT 5 . Known allergy iodine precludes endovascular procedure 6 . Treated tPA &gt; 4.5 hour time last know well 7 . Treated tPA 34.5 hour last know well AND follow ; age &gt; 80 , current anticoagulant use , history diabetes prior stroke , NIHSS &gt; 25 8 . Known hereditary acquire hemorrhagic diathesis , coagulation factor deficiency ; recent oral anticoagulant therapy INR &gt; 3 ( recent use one new oral anticoagulant exclusion estimate GFR &gt; 30 ml/min ) . 9 . Seizures stroke onset precludes obtain accurate baseline NIHSS 10 . Baseline blood glucose &lt; 50mg/dL ( 2.78 mmol ) &gt; 400mg/dL ( 22.20 mmol ) 11 . Baseline platelet count &lt; 50,000/uL 12 . Severe , sustain hypertension ( Systolic BP &gt; 185 mmHg Diastolic BP &gt; 110 mmHg ) 13 . Current participation another investigational drug device study 14 . Presumed septic embolus ; suspicion bacterial endocarditis 15 . Clot retrieval attempt use neurothrombectomy device prior 6 hrs symptom onset Neuroimaging 1 . ICA MCAM1 occlusion ( carotid occlusion cervical intracranial ; without tandem MCA lesion ) MRA CTA AND 2 . Target Mismatch Profile CT perfusion MRI ( ischemic core volume &lt; 70 ml , mismatch ratio &gt; /= 1.8 mismatch volume* &gt; /= 15 ml ) Alternative neuroimaging inclusion criterion ( perfusion image CTA/MRA technically inadequate ) : A ) If CTA ( MRA ) technically inadequate : Tmax &gt; 6 perfusion deficit consistent ICA MCAM1 occlusion AND Target Mismatch Profile ( ischemic core volume &lt; 70 ml , mismatch ratio &gt; 1.8 mismatch volume &gt; 15 ml determine RAPID software ) B ) If MRP technically inadequate : ICA MCAM1 occlusion ( carotid occlusion cervical intracranial ; without tandem MCA lesion ) MRA ( CTA , MRA technically inadequate CTA perform within 60 minute prior MRI ) AND DWI lesion volume &lt; 25 ml C ) If CTP technically inadequate : Patient screen MRI randomize neuroimaging criterion meet . Neuroimaging 1 . ASPECTS score &lt; 6 noncontrast CT ( baseline noncontrast CT perform ) 2 . Evidence intracranial tumor ( except small meningioma ) acute intracranial hemorrhage , neoplasm , arteriovenous malformation 3 . Significant mass effect midline shift 4 . Evidence internal carotid artery dissection flow limit aortic dissection 5 . Intracranial stent implant vascular territory precludes safe deployment/removal neurothrombectomy device 6 . Occlusions multiple vascular territory ( e.g. , bilateral anterior circulation , anterior/posterior circulation )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>endovascular</keyword>
	<keyword>endovascular procedure</keyword>
	<keyword>Mechanical Thrombectomy</keyword>
</DOC>